Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Now, California Acelyrin has broken ranks and filed to list on the Nasdaq under the SLRN ticker. There’s no indication yet on how much it is looking to raise with the IPO – its filing suggests ...

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...